Form 4: Robert Chess Reports Acquisition of Twist Bioscience Corp Shares

Director Robert Chess reports acquiring 4,472 shares of Twist Bioscience Corp stock and beneficially owning 21,113 shares directly and 42,528 indirectly through a trust.

Summary

• Robert Chess, a director of Twist Bioscience Corp, reported acquiring 4,472 shares of common stock on February 5, 2025.
• These shares were acquired at a price of $0.
• Following the transaction, Mr. Chess directly owns 21,113 shares of common stock.
• He also indirectly owns 42,528 shares through the Chess 1997 Trust, for which he and his spouse are the sole trustees and beneficiaries.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by a director. The acquisition itself could be interpreted as slightly positive, indicating confidence, but the document is primarily informational.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common for directors and officers of publicly traded companies. It provides transparency to investors regarding the trading activities of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a company director.

Key Dates